Healthcare
Verastem, Inc.(VSTM)
Live Price
Offline$4.12
-1.20% today
1Y Change
-11.26%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $410.00M
- Revenue Growth
- +209.1%
- EPS Growth
- +17.5%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verastem, Inc. (VSTM) is a Healthcare stock with a market cap of $410.00M and listed on NASDAQ. The stock last traded around $4.12 and down 11.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +209.1%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue +209.1%, EPS +17.5%, free cash flow -31.2% with operating margin -550.3% and ROIC -94.5%. Valuation already assumes a fairly strong business story at price/sales 13.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VSTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+209.1% vs +7.6% peer median
Operating Margin
Below sector median
-550.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +209.1% and EPS at +17.5%, with operating margin around -550.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +1.9% | -10.4% | -18.8% |
2026 Mar 4, 2026 | +20.4% | +5.9% | +6.5% | -4.5% |
2025 Nov 4, 2025 | -164.7% | +3.2% | +6.8% | +27.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VSTM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VSTM Max Drawdown
-66.39%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VSTM and SPY.
Company Overview
Verastem, Inc.
NASDAQ Global Market
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
- Leadership
- Daniel W. Paterson
- IPO Date
- Jan 27, 2012
- Employees
- 78
- Street Address
- 117 Kendrick Street
- Mailing
- Needham, MA, 02494
- Region
- Needham, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 292 4200
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 13.3
- Price/Book
- 8.7
Growth
- Revenue
- +209.1%
- EPS
- +17.5%
- Free Cash Flow
- -31.2%
Profitability
- Gross Margin
- 83.8%
- Operating Margin
- -550.3%
- Net Margin
- -677.6%
- ROE
- -1849.9%
- ROIC
- -94.5%
Balance Sheet
- Debt/Equity
- 1.52
- Current Ratio
- 3.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.